Ventilator Associated Pneumonia (VAP)
30% to 50% mortality rate of patients with VAP

The world's first breath test designed to detect & monitor pulmonary infections.

The only test that has the potential to differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.

Current standard of care vs Avisa BreathTest chart

Current standard of care chart
Avisa BreathTest chart

A Value-Based, Cost Advantaged Product would be a Win for Patient, Doctor, Hospital and Payer

Learn More About Clinical Applications

ABT Portfolio ABT Indications   IDE/Pivotal
Ventilator Associated Pneumonia     2023
Post-Covid 19 Bronchiectasis     Investigator Sponsored
Chronic Obstructive
Pulmonary Disease (COPD)
    Investigator Sponsored
Pneumonia (CAP)
    Investigator Sponsored
Cystic Fibrosis     Investigator Sponsored
Tuberculosis     Investigator Sponsored
Aspergillus/Coccii Fungus     Investigator Sponsored
Clostridium Difficile (C. diff)     Developmental

Interested in learning more?

Contact us today to speak with an Allora Expert!

Contact Us

Subscribe to receive our press releases

Stock Info:
CSE:   AVBT $0.00